SLC3A2 and osteosarcoma: While Zhu et al. revealed that SLC3A2 was upregulated in human osteosarcoma and promoted disease progression via the PI3K/Akt signaling pathway (Zhu et al., 2017), our study did not find SLC3A2 could reflect a better survival interval for patients with SARC.